Biotech CEO Just Got FDA Approval That Sent Stock Up 6% - Here's Why
Key Points
- Krystal Biotech's Vyjuvek therapy for treating a rare skin c...
When the FDA gives your gene therapy the green light to treat babies, your stock doesn't just rise - it moonwalks. Krystal Biotech (NASDAQ: KRYS) discovered this firsthand when their Vyjuvek therapy got approved for treating dystrophic epidermolysis bullosa (DEB) in newborns, sending shares up 6.01% to $152.32.
The Baby Steps That Matter Most
Let's break this down without the medical jargon. DEB is a rare genetic condition that makes your skin as fragile as tissue paper - imagine having to change wound dressings constantly while dealing with severe pain. Now imagine telling parents they ...
While we have taken every measure to build an AI pipeline that generates credible and accuracte news, we still encourage you to conduct your own research before making investment decisions. InsAIght's content should not be considered professional financial or trading advice.